New: NCI-funded clinical trial search
Mednet Logo
SpecialtiesRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?

1
2 Answers

Mednet Member
Mednet Member
Cardiology · New York Medical College

I would avoid initiating empiric immunosuppressive therapies without a firm diagnosis of sarcoidosis. I will mention however that the latest Japanese Circulation Society criteria for the diagnosis of sarcoidosis do include criterion for the non-invasive diagnosis of likely cardiac sarcoidosis based ...

Do you recommend allopurinol desensitization in gout patients who develop a rash on allopurinol therapy?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · National institues of Health

I don't recommend desensitization for allopurinol-allergic patients. There was a time when this made sense due to the lack of a viable alternative therapy. The process is cumbersome in a private practice setting and not as simple as providing the patient with a prescription for febuxostat.Febuxostat...

How often do you draw screening ANAs for discoid lupus?

3 Answers

Mednet Member
Mednet Member
Rheumatology · Harvard Medical School

Because a positive ANA is associated with an increased risk of progression to SLE in patients with discoid lupus, I routinely check an ANA at the initial visit in virtually all patients. If negative, I repeat it only if new symptoms concerning systemic involvement arise (e.g., joint pain, cytopenias...

How would you approach the evaluation and management of a patient with rheumatoid arthritis receiving leflunomide who presents with progressive peripheral pulmonary cavitary nodules, with biopsy revealing necrotizing granulomatous inflammation?

1
2 Answers

Mednet Member
Mednet Member
Pulmonology · National Jewish Health

Given the association between leflunomide and nodules with necrosis and giant cells (though quite rare), I would consider stopping leflunomide and moving to another agent. I would, of course, make sure that cultures are negative on those nodules, given it could be mycobacterial, fungal, or even GPA.

How do you explain the concept of CAR-T therapy and why it may work to patients with autoimmune disease who are interested in pursuing a clinical trial?

3 Answers

Mednet Member
Mednet Member
Rheumatology · Cleveland Clinic

In full transparency, I have not personally obtained informed consent from a patient immediately before CAR-T or a related cellular therapy. My center has a highly active immune therapeutics program, however, and I have spoken and written extensively about this area. I also serve on our health syste...

Are there clinical, laboratory, or imaging features that can help distinguish primary Sjögren’s syndrome from secondary Sjögren’s in patients with overlapping inflammatory arthritis or positive rheumatoid factor?

1 Answers

Mednet Member
Mednet Member
Rheumatology · University of California, Berkeley and San Francisco

Such a good query. I don't really know, as associated SjD has been understudied. In my experience, associated Sjogren's does not look that different from Sjogren's alone. We have seen high ocular staining scores and markedly reduced unstimulated salivary flow in associated SjD (SLE, RA). In SjD, the...

Can you use leflunomide and rituximab in a patient with both multiple sclerosis and rheumatoid arthritis?

3
4 Answers

Mednet Member
Mednet Member
Neurology · Touro University

It is rare for a patient to have both diseases, but immunosuppressive therapy can be used for the management of both conditions. A study published in 2021 investigated the use of a combination of rituximab and leflunomide in rheumatoid arthritis (Behrens et al., PMID 33738492). Rituximab has previou...

Is there a period of time after which you would not resume ICI after a patient has had an irAE and required a prolonged steroid taper?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Typically if a patient has required treatment with steroids for four to six months, it was because their irAE was significant (grade 2-4) and refractory to initial treatment. If the patient received combination immunotherapy, such as anti-CTLA-4 and anti-PD-1 agents, one could consider resuming the ...

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...

How do you approach evaluation and management of a patient with recurrent monoarticular inflammatory arthritis of unclear etiology? 

4
4 Answers

Mednet Member
Mednet Member
Rheumatology · Berkshire Health Systems

Routine testing will not identify Lyme disease, although the WBC count is higher than usual. If the antibiotic does not target B. burgdorferi, recurrence might mean inappropriate therapy previously. WBC count is WAAAY too high for mere trauma or internal derangement. Anything else to suggest psorias...